Acne
Conditions
Brief summary
A study of safety and efficacy of topical methyaminlevulinate 80mg/g with and without occlusion followed by red light exposure in subjects with facial acne.
Detailed description
Photocure ASA has developed a cream formulation containing methyl aminolevulinate (MAL), an ester of ALA. There is extensive experience with the safety of MAL-PDT in humans. This study will assess safety and efficacy of four treatments with methylaminolevulinate (MAL) at 80 mg/g performed with and without occlusion and followed by red light exposure 90 minutes later in subjects with facial acne vulgaris. Subjects will be randomized to one of two groups of 20 subjects: Group 1 will receive 25 J/cm2 of red light (45 mW/cm2) and group 2 will receive 37 J/cm2 of red light (90 mW/cm2). For each subject one side of the face will be randomized to receive MAL for 90 minutes without occlusion and the other side of the face will receive MAL for 90 minutes with occlusion.
Interventions
DRUGMAL
80 mg/g cream one administration with incubation for 90 minutes
Sponsors
Photocure
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subject willing to use an adequate contraceptive method or is surgically sterile, post menopausal, abstinent or with a same-sex partner. Adequate means of contraception include; IUD in use 30 days prior to day 0, barrier methods and spermicide in use atleast 14 days prior to day 0 or oral contraceptive in use for at least 6 months prior to day 0 * Age 18 or older * Capable of giving informed consent * Diagnosis of acne vulgaris on the face with at least 10 inflammatory lesions on both sides of the face at screening and day 0 * Global acne severity assessment score ≥ 3 at the screening and day 0 visit.
Exclusion criteria
* Allergy to methylaminolevulinate or any component of the vehicle * Acne fulminans or conglobata on the face * Clinical significant sensitivity to visible light, porphyria or porphyrin sensitivity * Use of any topical treatment for acne on the face within the previous 2 weeks before day 0 * Any use of systemic antibiotics within 1 month prior to day 0 or use of isotretinoin within 1 year prior to Day 0 * Exposure to ultraviolet radiation (UVB phototherapy, sun tanning salons) within 4 weeks of Day 0 * Use of any investigational drug within 4 weeks of Day 0 * Alcoholism or drug abuse in the past year * Any unstable or serious medical condition at the discretion of the investigator * Current pregnancy or lactation * Use of hormonal contraceptives solely for control of acne * Current use of oral contraceptives (unless subject is on a stable dose e.i. at least six months of treatment prior Day 0), testosterone or any other systemic hormonal treatment * Any serious dermatological disorder, including malignancies that would either put the subject at risk or interfere with efficacy or safety evaluations * Fitzpatrick phototype V or VI (inadequate penetration of red light in dark skin subjects) * Subjects with extensive facial hair (e.g. beard) that would either impair red light exposure or interfere with lesion evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the number of inflammatory acne lesions according to time on the side with occlusion and the side without occlusion for subjects with facial acne vulgaris exposed to 25 J/cm2 and 37 J/cm2 of red light. | 4 and 12 weeks after last PDT session. |
Secondary
| Measure | Time frame |
|---|---|
| Exposed to 25 J/cm2 and 37 J/cm2 of red light and with and withut occlusion :-Compare number of non-inflammatory acne lesions. -Safety assesment of MAL-PDT. -Evaluate PAP photobleaching. | At each treatment visit and 2 and 7 days after first PDT treatment visit. |
Countries
Canada
Outcome results
None listed